Epigenetix is a cutting-edge biotechnology company dedicated to understanding and harnessing epigenetic mechanisms to develop transformative therapies for diseases with high unmet medical needs, including various cancers, neurodegenerative disorders, and rare genetic conditions. Our innovative platform integrates advanced genomic sequencing, computational biology, and novel drug discovery technologies to identify and target epigenetic modifiers. We are committed to translating groundbreaking scientific insights into clinically meaningful treatments that can significantly improve patient outcomes. Our research focuses on identifying novel biomarkers for patient stratification and developing precision medicines tailored to individual epigenetic profiles.
Serves as the primary center for research and development, corporate strategy, business development, and administrative operations.
State-of-the-art laboratories equipped for advanced molecular biology, cell biology, and high-throughput screening; dedicated bioinformatics and computational biology suites; collaborative open-plan office spaces.
A dynamic and collaborative environment that fosters innovation, scientific rigor, and a patient-centric approach. Employees are encouraged to take initiative and contribute to a culture of continuous learning and discovery.
Its location in Kendall Square provides unparalleled access to a rich ecosystem of talent, academic research, venture capital, and potential pharmaceutical partners, crucial for accelerating drug development.
Epigenetix supports its global mission through its headquarters in Cambridge, MA, a European operations hub in Lausanne, Switzerland, and a West Coast innovation office in South San Francisco, CA. These locations enable us to conduct global clinical trials, foster international research collaborations, and engage with diverse talent pools and partners worldwide. Our functions supported globally include research and development, clinical trial management, regulatory affairs, business development, and strategic partnerships.
123 Helix Drive, Kendall Square
Cambridge
MA
USA
Address: Biopôle, Route de la Corniche 45
To spearhead clinical development activities in Europe, leverage the strong Swiss and European life sciences network, and facilitate regulatory interactions with the EMA.
Address: 789 Genome Way, Suite 200
To tap into the Bay Area's rich biotech talent pool, foster collaborations with leading academic and tech companies, and expand investor relations on the West Coast.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Epigenetix' leadership includes:
Epigenetix has been backed by several prominent investors over the years, including:
Epigenetix has seen strategic additions to its executive team in the past year to bolster its clinical development and operational capabilities, with no major executive departures.
Discover the tools Epigenetix uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Epigenetix commonly uses the email format of first initial followed by last name. For example, for an employee named Jane Doe, the email would likely be jdoe@epigenetix-pharma.com. Variations might exist based on common names.
flast@epigenetix-pharma.com (e.g., jdoe@epigenetix-pharma.com), first.last@epigenetix-pharma.com
Format
athorne@epigenetix-pharma.com
Example
90%
Success rate
FierceBiotech • April 15, 2024
Epigenetix announced the closure of a $120 million Series C financing round, co-led by new investor ChromoTech Ventures and existing investor GeneVenture Capital. The proceeds will be used to advance its lead drug candidate, EPZ-101, for solid tumors into Phase IIb clinical trials and to expand its pipeline of epigenetic modulators for neurodegenerative diseases....more
Endpoints News • November 08, 2023
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Epigenetix's lead investigational therapy, EPZ-101, for the treatment of patients with relapsed/refractory glioblastoma. This designation aims to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need....more
BioCentury • July 20, 2023
Epigenetix presented new preclinical data at the Alzheimer's Association International Conference (AAIC) demonstrating the potential of its epigenetic modulator, EPZ-205, in a model of Alzheimer's disease. The data showed significant improvements in cognitive function and reduction in neuropathological markers....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Epigenetix, are just a search away.